Envestnet Asset Management Inc Hepion Pharmaceuticals, Inc. Transaction History

Envestnet Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.31 - $1.06 $14,281 - $48,833	-46,069 Reduced 22.7%	156,909 $122,000
Q4 2022 Feb 07, 2023	BUY	$0.27 - $11.9 $31,167 - $1.37 Million	115,437 Added 131.87%	202,978 $60,000
Q3 2022 Nov 10, 2022	BUY	$0.51 - $10.4 $14,018 - $285,864	27,487 Added 45.77%	87,541 $44,000
Q2 2022 Aug 03, 2022	BUY	$0.57 - $1.22 $1,297 - $2,776	2,276 Added 3.94%	60,054 $34,000
Q1 2022 May 04, 2022	SELL	$0.93 - $1.29 $13,251 - $18,381	-14,249 Reduced 19.78%	57,778 $75,000
Q4 2021 Feb 04, 2022	BUY	$1.14 - $1.58 $38,314 - $53,102	33,609 Added 87.48%	72,027 $82,000
Q3 2021 Oct 07, 2021	SELL	$1.39 - $2.1 $75,756 - $114,452	-54,501 Reduced 58.65%	38,418 $59,000
Q2 2021 Aug 04, 2021	BUY	$1.56 - $2.26 $104,335 - $151,153	66,882 Added 256.87%	92,919 $184,000
Q1 2021 May 04, 2021	BUY	$1.77 - $2.98 $46,085 - $77,590	26,037 New	26,037 $48,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $37.4M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.